Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel – an update

Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive n...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheson, Bruce D., Brugger, Wolfram, Damaj, Gandhi, Dreyling, Martin, Kahl, Brad, Kimby, Eva, Ogura, Michinori, Weidmann, Eckhart, Wendtner, Clemens-Martin, Zinzani, Pier Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840280/
https://www.ncbi.nlm.nih.gov/pubmed/26592922
http://dx.doi.org/10.3109/10428194.2015.1099647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840280/
https://www.ncbi.nlm.nih.gov/pubmed/26592922
http://dx.doi.org/10.3109/10428194.2015.1099647

Ejemplares similares